ASPECTS OF ANESTHESIOLOGICAL MANAGEMENT DURING SURGICAL INTERVENTIONS IN PATIENTS WITH VON WILLEBRAND DISEASE
DOI:
https://doi.org/10.32782/2411-9164.22.1-2Keywords:
von Willebrand disease, von Willebrand factor, factor VIII, anesthetic management, surgical treatmentAbstract
This article highlights the challenges associated with hereditary coagulopathies, focusing on von Willebrand disease (VWD) – the most prevalent inherited bleeding disorder, which significantly complicates surgical interventions due to impaired hemostasis. The review outlines the etiology, pathogenesis, and clinical manifestations of VWD and highlights the importance of tailored perioperative management strategies. Emphasis is placed on the necessity of individualized treatment approaches, particularly the optimization of von Willebrand factor (vWF) and factor VIII (FVIII) levels, which are critical to minimizing bleeding risks in the perioperative period. Key anesthetic considerations include antifibrinolytic therapy, replacement therapy using fresh frozen plasma, cryoprecipitate, platelet concentrates, and FVIII concentrates. The importance of meticulous hemostatic monitoring, patient-specific treatment planning, and personalized dosing regimens is underscored to improve outcomes and reduce the risk of thromboembolic complications.
References
Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, Grow JM, Kouides P, Laffan M, Lavin M, Leebeek FWG, O’Brien SH, Ozelo MC, Tosetto A, Weyand AC, James PD, Kalot MA, Husainat N, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021 Jan 12;5(1):301–325. doi: 10.1182/bloodadvances.2020003264. PMID: 33570647; PMCID: PMC7805326
Miesbach W, Berntorp E. Von Willebrand disease – the ‘Dos’ and ‘Don’ts’ in surgery. Eur J Haematol. 2017 Feb;98(2):121–127. doi: 10.1111/ejh.12809. Epub 2016 Oct 14. PMID: 27622750
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs- Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O’Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021 Jan 12;5(1):280–300. doi: 10.1182/bloodadvances.2020003265. PMID: 33570651; PMCID: PMC7805340
Miesbach W. Perioperative management for patients with von Willebrand disease: Defining the optimal approach. Eur J Haematol. 2020 Oct;105(4):365–377. doi: 10.1111/ejh.13462. Epub 2020 Jul 3. PMID: 32496614
Schinco P, Castaman G, Coppola A, Cultrera D, Ettorre C, Giuffrida AC, Marchesini E, Marino R, Milan M, Molinari C, Siboni SM, Zanon E, Federici AB. Current challenges in the diagnosis and management of patients with inherited von Willebrand’s disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis. Blood Transfus. 2018 Jul;16(4):371–381. doi: 10.2450/2017.0354–16. Epub 2017 May 26. PMID: 29313798; PMCID: PMC6034771
Leebeek FW, Eikenboom JC. Von Willebrand’s Disease. N Engl J Med. 2016 Nov 24;375(21):2067–2080. doi: 10.1056/NEJMra1601561. PMID: 27959741
Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994 Apr;71(4):520–5. PMID: 8052974.
Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007 Jun;5(6):1115–24. doi: 10.1111/j.1538-7836.2007.02562.x. PMID: 17403090
Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence- based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008 Mar;14(2):171–232. doi: 10.1111/j.1365-2516.2007.01643.x. PMID: 18315614
Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014 Nov;167(4):453–65. doi: 10.1111/bjh.13064. Epub 2014 Aug 12. PMID: 25113304; PMCID: PMC4283483.
Persson J, Flisberg P, Lundberg J. Thoracic epidural anesthesia and epidural hematoma. Acta Anaesthesiol Scand. 2002 Oct;46(9):1171–4. doi: 10.1034/j.1399-6576.2002.460921.x. PMID: 12366518
Pérez-Barrero P, Gil L, Martínez C, Bueno AB, Casado AI, Oro J. Tratamiento con desmopresina (DDAVP) previo a la analgesia epidural del parto a una paciente con enfermedad de von Willebrand tipo I [Treatment with desmopressin before epidural anesthesia in a patient with type I von Willebrand disease]. Rev Esp Anestesiol Reanim. 2003 Dec;50(10):526–9. Spanish. PMID: 14737779.
Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012 May;18(3):e173–87. doi: 10.1111/j.1365-2516.2012.02758.x. Epub 2012 Feb 15. PMID: 22335611.
Willers A, Arens J, Mariani S, Pels H, Maessen JG, Hackeng TM, Lorusso R, Swol J. New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices. Membranes (Basel). 2021 Aug 12;11(8):617. doi: 10.3390/membranes11080617. PMID: 34436380; PMCID: PMC8399034].
